Group items tagged

Microplates are an important part of many laboratory experiments. They are often used to measure the results of a process or to test a product. When working with microplates, it is important to use the right closure and sealing method to ensure accurate results. This article will discuss the different types of closures and seals available, as well as how to choose the right one for your needs. HEAT SEALING METHOD One of the most common methods for sealing microplates is the heat seal method. This method uses a heating element to melt the top layer of the plate, which then bonds to the bottom layer. Heat sealing is a quick and easy way to seal a microplate, and it is often used for plates that will be stored for long periods. For this reason, heat sealing is the preferred method for sealing storage plates. Heat sealing is also one of the most cost-effective methods for sealing microplates. If you are interested to learn more about heat sealing, you may be surprised to find that there are many pieces of heat sealing equipment for sale at a very reasonable price. You just need to take the time to find the right one for your needs. As much as possible, choose the one with adjustable temperature settings so you can find the perfect heat for your microplates. More often than not, 225 degrees Fahrenheit is the ideal temperature for heat sealing.

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labelled a global health emergency by the World Health Organization. The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox. Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have been proven to help hasten recovery in those who develop the disease. The UK has over 3,000 confirmed cases of monkeypox. The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks. Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.

The Pharmacist' Defence Association (PDA) has welcomed the General Pharmaceutical Council (GPhC) and the Pharmaceutical Society of Northern Ireland (PSNI)'s plan to ensure a more robust, fair and positive experience for trainees, provisionally registered and potential pharmacists who will be sitting the November 2022 assessment. "Many candidates at the latest (June 2022) assessment experienced significant delays, technical issues, inadequate invigilation, and disturbances in test centres around the UK as the newly appointed company BTL ran the high-stakes pharmacist examinations for the first time. The next online exam is due in November 2022 and the PDA welcome proposed improvements to be introduced before that sitting," said the association. For some, provisional registration was the accepted response from the GPhC, but for others, such as potential pharmacists who did not want the provisional role, those unable to find a suitable provisional post, or some that did not meet the criteria for provisional registration, they found themselves in financial difficulties through no fault of their own, having reasonably expected to have joined the register in the Summer.

The National Health Service England (NHSE) aims to eliminate cervical cancer by 2040 by making the lifesaving Human Papillomavirus (HPV) vaccination easily accessible to people and increasing cervical screening uptake. In addition to the campaign, the NHS is expanding the outreach of cervical screening more than ever before. Last year, the health service invited over five million people aged 25 to 64 for the screening, out of which 3.5 million were tested. Moreover, self-sampling will be trialled to see if the service can introduced as part of national screening. England is among the first countries in the world to set this elimination ambition, which could save thousands of lives every year in the country. Amanda Pritchard, chief executive of Officer of NHS England, announced the health service's new goal and how to achieve it at the NHS Providers' annual conference today (15 November).

AstraZeneca UK has revised the expiry dates for certain batches of Fluenz Tetra nasal spray vaccines as a precautionary measure, after finding that their potency (strength) dropped faster than predicted once thawed, during routine testing. The Medicines and Healthcare products Regulatory Agency (MHRA) has been informed by the manufacturer that the printed expiry date for a limited number of batches is "incorrect." However, the MHRA has assured patients that the affected batches are safe to use and fully effective within the amended expiry date. If the vaccine is administered after the amended expiry date, it may be less effective in protecting against flu, it said. The UK regulatory authority also reiterated that it "keeps the safety of medicines, including vaccines, under review, and acts where necessary to protect patients and the public."

Thanks to the NHS primary care access recovery plan, more than 23 million people can now view test results and check their consultation notes online without needing to contact their GP practice. NHS England on Monday (4 December) announced that over 81 GP practices in England (more than four in five) are now giving patients access to their new health records online through the NHS App. In May, the NHS announced the primary care access recovery plan setting a target of 9 in 10 GP practices offering patients access to their records through the NHS App by March 2024. By making access to healthcare easier and quicker, the NHSE also aims to free up to 10 million GP appointments a year by next winter.

Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes, it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes. Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of supplying medicines. This relationship, however, may be underutilised. Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being of PwDs.

The Digital Medicines Transformation Portfolio (DMTP) was able to deliver the electronic prescription service (EPS) in Wales - just 20 months after starting the project - with support from key partners in the NHS and industry. Patients in Rhyl were the first to benefit from the new service, which allows GPs to send prescriptions electronically to the patient's choice of community pharmacy, without the need for a paper form. The new EPS service is currently in a live testing phase, with a phased roll out across Wales expected from January 2024. DMTP, which is hosted by Digital Health and Care Wales (DHCW) has worked closely with NHS England, who provided the core EPS platform that has been developed for use in Wales. NHS Wales Shared Services Partnership has also made a major contribution in the project, incorporating digital reimbursement to pharmacies and putting security measures in place.

The Department of Health (DoH) Northern Ireland is reminding the public to think Pharmacy First this winter to stay well and reduce demands on other parts of their health service. Under this new advanced service, a local pharmacy can provide treatment and advice on a range of health conditions including common colds, stomach upsets, ear aches, diarrhoea, head lice, mouth ulcers and thrush. Pharmacies will also directly provide emergency contraception and advice and treatment for uncomplicated Urinary Tract Infections (UTI) for women aged 16 to 64 years without the need for a GP appointment, the department said. Further the public are informed that 42 community pharmacies across the country will be providing a sore throat service this winter, involving advice, testing for infection and treatment, if necessary.

A total of 37 more cases of monkeypox have been detected in England and Scotland, public health officials said on Monday, taking the total to 57. Thirty-six confirmed cases were found in England, and one north of the border, the UK Health Security Agency and Public Health Scotland said. The UKHSA said it was now advising high-risk contact cases of confirmed cases who have not tested positive or developed symptoms to isolate for up to 21 days. It has also bought supplies of smallpox vaccine, which is being offered to close contacts to reduce the risk of symptomatic infection and severe illness. Chief medical adviser Susan Hopkins said contact tracing was helping to limit the close-contact spread of the virus, which causes a chickenpox-like rash. "Because the virus spreads through close contact, we are urging everyone to be aware of any unusual rashes or lesions and to contact a sexual health service if they have any symptoms," she added in a statement.

Just over 60 per cent candidates have passed the first four-country common registration assessment for pharmacists, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI). Out of a total of 959 candidates who sat the assessment in four countries on 16 November, 584 candidates have passed - recording an overall pass rate of 60.9 per cent. The registration assessment is one of the ways trainee pharmacists can demonstrate that they understand how to apply knowledge appropriately and in a timely way, to make professional judgements in pharmacy practice. Passing the registration assessment is a vital element of being eligible to apply to become a registered pharmacist. In the November assessment, 43 per cent candidates sat for the first time, 45 per cent for the second time and 12 per cent for the third time.

GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot. The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators. The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said. "To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022." No safety concerns were identified. This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

British scientists said on Thursday (December 30) they would be studying whether higher doses of a cheap and widely used steroid called dexamethasone could work better for patients with severe Covid-19 compared to the standard low doses. Last year, the same scientists conducting the large trial, dubbed RECOVERY, showed that dexamethasone was able to save the lives of Covid-19 patients in what was called a "major breakthrough" in the coronavirus pandemic. They had found that a 6 mg daily dose of dexamethasone, which is used to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill Covid-19 patients in hospitals. "Given how quickly the Omicron variant is spreading, we can expect to see patients admitted to hospital with severe Covid-19 for a while to come," said Peter Horby, an Oxford University professor co-leading the trial.

More than 5,000 vulnerable people have enrolled for the ground-breaking Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) study on life-saving antivirals. With this the UK is now one step closer to rolling out the innovative medicines, which would help reduce the severity of symptoms and the risk of hospitalisation or death. Success of the study would eventually help to ease pressures on the NHS. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result.

The world's first human challenge trial in which volunteers were deliberately exposed to Covid-19 to advance research into the disease was found to be safe in healthy young adults, one of the companies running the study said on Wednesday. The data supports the safety of this model which could theoretically provide a "plug and play" platform for testing therapies and vaccines using the original Covid-19 strain as well as variants of the virus, Open Orphan, which carried out the study, said in a statement. Open Orphan is running the project, launched a year ago, with Imperial College London, the UK government's vaccines task force and the clinical company  hVIVO. The trial infected 36 healthy male and female volunteers aged 18-29 years with the original SARS-CoV-2 strain of the virus and closely monitored them in a controlled quarantined setting. They will be followed up for 12 months after discharge from the quarantine facility.

The NHS catch up plan to bring down the number of waiters in the diagnostic list has helped in witnessing a drop of 6,500 people waiting more than two years for elective treatment between February and March. While those waiting more than 78 weeks - a year and a half - dropped by 5,700 over the same period. According to latest month data published today (May 12) more than two million diagnostic tests were carried out - the highest total for March on record - and an increase of 217,000 on the previous month (Feb 2022). The data revealed that it was also the highest month on record for cancer referrals, with 253,796 people checked in March alone - an almost 40 per cent increase on the number of checks made in March 2020. Alongside this, almost 30,000 people started treatment for cancer (28,378) - the second highest number on record. This is second only to March 2020, with 28,881 people starting treatment.

Pfizer has recalled all stocks of Accupro - including 5mg, 10mg, 20mg, 40mg film-coated tablets - as a precautionary measure due to the identification of a nitrosamine above the acceptable limit. "Following testing, N-nitroso-quinapril, has been observed at a level above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. The recall is at pharmacy and wholesaler level," the Pharmaceutical Services Negotiating Committees (PSNC) reported. The Department of Health and Social Care (DHSC) said: "All strengths of quinapril (Accupro) tablets have been recalled with a resupply date to be confirmed. Pfizer are the sole supplier of quinapril tablets in the UK. Alternative ACE inhibitors remain available and can support an uplift in demand."

Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.

An Indian court has sentenced two pharmaceutical company executives to two-and-half years in jail for exporting substandard drugs to Vietnam a decade ago, months after the WHO linked their cough syrups to the deaths of children in Gambia. India suspended production at Maiden Pharmaceuticals in October last year for violations of manufacturing standards after the World Health Organization said four of its cough syrups may have killed dozens of children in Gambia. The company has denied its drugs were at fault for the deaths in Gambia and tests by an Indian government laboratory found there were no toxins in them. The company had been facing legal difficulties for years over suspected shoddy products. A court in Sonipat, near New Delhi, where Maiden has its main production facility, ordered jail for company founder Naresh Kumar Goel and technical director M.K. Sharma for exporting heartburn medicine "not of standard quality" to Vietnam.